SELLAS Life Sciences Group Inc. (NASDAQ: SLS)
$1.14
+0.0500 ( +4.59% ) 1.9M
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Market Data
Open
$1.14
Previous close
$1.09
Volume
1.9M
Market cap
$65.84M
Day range
$1.08 - $1.28
52 week range
$0.50 - $1.90
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jan 25, 2024 |
4 | Insider transactions | 1 | Jan 25, 2024 |
4 | Insider transactions | 1 | Jan 25, 2024 |
8-k | 8K-related | 21 | Jan 08, 2024 |
8-k | 8K-related | 12 | Jan 03, 2024 |
8-k | 8K-related | 12 | Dec 22, 2023 |
8-k | 8K-related | 13 | Dec 13, 2023 |
4 | Insider transactions | 1 | Dec 08, 2023 |
4 | Insider transactions | 1 | Dec 08, 2023 |
4 | Insider transactions | 1 | Dec 08, 2023 |